589 related articles for article (PubMed ID: 15877591)
1. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
2. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
3. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
Argenta C; Ferreira MA; Sander GB; Moreira LB
Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
[TBL] [Abstract][Full Text] [Related]
4. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
[TBL] [Abstract][Full Text] [Related]
5. Safety and low molecular weight heparin in older people in a hospital with ambulatory care.
Chan DK; Ong B; Almafragy H; Karr M; Hung AW; Liu JG
Arch Gerontol Geriatr; 2006; 43(2):233-41. PubMed ID: 16359739
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
8. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
9. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.
Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Germain G; Bookhart B; Pollack CV
J Med Econ; 2016; 19(1):84-90. PubMed ID: 26390315
[TBL] [Abstract][Full Text] [Related]
10. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Santamaría A; Juárez S; Reche A; Gómez-Outes A; Martínez-González J; Fontcuberta J;
Int J Clin Pract; 2006 May; 60(5):518-25. PubMed ID: 16700847
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
13. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
14. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
15. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.
Kahler ZP; Beam DM; Kline JA
Acad Emerg Med; 2015 Jul; 22(7):796-802. PubMed ID: 26111453
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.
Hull RD
Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Büller HR; Agnelli G; Hull RD; Hyers TM; Prins MH; Raskob GE
Chest; 2004 Sep; 126(3 Suppl):401S-428S. PubMed ID: 15383479
[TBL] [Abstract][Full Text] [Related]
19. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A
J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962
[TBL] [Abstract][Full Text] [Related]
20. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
